Status:
COMPLETED
Telemedicine for Follow-up of Systemic Lupus Erythematosus
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
SLE
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Background Patients with systemic lupus erythematosus (SLE) might be more susceptible to Covid-19 due to the underlying disease, co-morbidities and the use of immunosuppressive drugs. The investigator...
Detailed Description
There is a single-center pragmatic randomized controlled trial over a 12-month period. The study will be performed at the Rheumatology clinics at the Prince of Wales Hospital, which is a regional hosp...
Eligibility Criteria
Inclusion
- Fulfilling the 2019 European League Against Rheumatism/American College of Rheumatology classification criteria
- Over 18 years of age
- able to speak or understand Chinese
- willing to come back for routine blood and urine tests
- possess the technology needed to conduct a TM visit
Exclusion
- pregnant
- incapable of answering a questionnaire
Key Trial Info
Start Date :
May 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2022
Estimated Enrollment :
144 Patients enrolled
Trial Details
Trial ID
NCT04368299
Start Date
May 1 2020
End Date
January 31 2022
Last Update
March 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Chinese University of Hong Kong
Hong Kong, Hong Kong